BluePath Solutions, a leading health economics and value communication consulting firm, has acquired Qualia Bio.
Concise summaries of key terms, topics, or policies for subscribers on pharma, biotech, business, and policy.
Our team is known for policy analysis, particularly evidence-based analysis, which we publish as inferences.
Deep dives into topics on pharmaceutical policies, regulations, and economics in biotech
Stay up to date with the latest biotech data analytic news
We collect, aggregate, curate and enrich medical datasets from various sources. Access these datasets with our research tools to uncover meaningful insights. Then download relevant datasets for further analysis.
A new tool to track prices and price concessions across physician administered drugs, by individual therapies, therapeutic classes, or manufacturers.
Pricescape provides a more complete picture of incomplete data.
Early access
This tool estimates reimbursement for PPS Exempt Cancer Hospitals (PCHs) and details the use of chimeric antigen receptor (CAR) T cell therapies in the economic context
Calculate the Base Payments by Provider and Medicare severity diagnosis related group.
This tool provides an interface to the Surveillance, Epidemiology, and End Results (SEER) cancer statistics data.
The tool makes it easy to understand which cancers are the most common and how their incidence has changed over time.
Interact with data published by the Medicare & Medicaid Services (CMS) to quickly estimate Medicare payments for acute care hospital inpatient stays.
This tool helps you easily navigate the complexities of the Inpatient Prospective Payment System (IPPS) rules and weightings that are updated annually.
Qualia Bio was born out of an idea to help ensure patients' access to innovative and life-saving treatments. To champion said access, we provide insightful political economics and regulatory support for the biotech and finance industries. We're here to help manufacturers or investors monetize a therapy's value attributes, integrate government policies, assess a therapy's potential uptake, or attain a drug class's discount or rebates pressure.
Through our actionable data insights, we make drug acquisitions and market access seamless. We provide resources, apps, and models to as many organizations as possible (not just the biggest companies). We are injecting a necessary step in market access: quick analyses that can be high-level or in-depth, so that your organization can spend resources where they are truly needed.
Read morenavigate_nextSign up now with 1 month free trial. Downgrade at anytime.